Description:
Cancer is a condition where cells in a specific part of body grow and reproduce
uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and
Non-Small Cell Lung Cancer (NSCLC). AML (blood cancer) is cancer of the white blood cells
(WBC). NSCLC (solid tumor) is a disease in which cancer cells form in the tissues of the
lung. The purpose of this study is to determine recommended phase 2 dose (RP2D) and to see if
the study drug is safe and able to treat patients who have AML and NSCLC.
ABBV-184 is an investigational drug being developed for treatment of cancer. The study has
two arms and two phases: AML arm and NSCLC arm; dose escalation and dose expansion phase.
Adult participants with diagnosis of AML or NSCLC will be enrolled. In dose escalation phase,
around 36 participants will be enrolled in each arm. In dose expansion phase, around 20
participants will be enrolled in each arm. The study will be conducted in approximately 50
sites across 10 countries.
Participants will receive weight based intravenous (IV) infusion of ABBV-184 once a week. At
the beginning of the study, visits will occur daily during hospitalization followed by less
frequently over time.
There will be a higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of treatment will be checked by medical assessments, blood tests, checking
for side effects, and questionnaires.
Title
- Brief Title: A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
- Official Title: A Phase 1 First in Human, Multicenter, Open-Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics, and RP2D of ABBV-184 in Subjects With Previously Treated Cancers
Clinical Trial IDs
- ORG STUDY ID:
M19-747
- SECONDARY ID:
2019-003434-16
- NCT ID:
NCT04272203
Conditions
- Acute Myeloid Leukemia (AML)
- Non Small Cell Lung Cancer
- Cancer
Interventions
| Drug | Synonyms | Arms |
|---|
| ABBV-184 | | Dose Escalation: Participants With AML |
Purpose
Cancer is a condition where cells in a specific part of body grow and reproduce
uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and
Non-Small Cell Lung Cancer (NSCLC). AML (blood cancer) is cancer of the white blood cells
(WBC). NSCLC (solid tumor) is a disease in which cancer cells form in the tissues of the
lung. The purpose of this study is to determine recommended phase 2 dose (RP2D) and to see if
the study drug is safe and able to treat patients who have AML and NSCLC.
ABBV-184 is an investigational drug being developed for treatment of cancer. The study has
two arms and two phases: AML arm and NSCLC arm; dose escalation and dose expansion phase.
Adult participants with diagnosis of AML or NSCLC will be enrolled. In dose escalation phase,
around 36 participants will be enrolled in each arm. In dose expansion phase, around 20
participants will be enrolled in each arm. The study will be conducted in approximately 50
sites across 10 countries.
Participants will receive weight based intravenous (IV) infusion of ABBV-184 once a week. At
the beginning of the study, visits will occur daily during hospitalization followed by less
frequently over time.
There will be a higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of treatment will be checked by medical assessments, blood tests, checking
for side effects, and questionnaires.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Dose Escalation: Participants With AML | Experimental | Participants with relapsed or refractory (R/R) AML will receive escalating doses of ABBV-184 | |
| Dose Escalation: Participants With NSCLC | Experimental | Participants with relapsed or refractory (R/R) NSCLC will receive escalating doses of ABBV-184 | |
| Dose Expansion: Participants With AML | Experimental | Participants with R/R AML will receive ABBV-184 at recommended Phase 2 dose (RP2D) determined in dose escalation phase for AML | |
| Dose Expansion: Participants With NSCLC | Experimental | Participants with R/R NSCLC will receive ABBV-184 at RP2D determined in dose escalation phase for NSCLC | |
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of acute myeloid leukemia (AML) or non-small cell lung cancer (NSCLC).
- Participants must consent to hospitalization for at least 72 hours following the first
two doses of ABBV-184 in Cycle 1.
- Participants must have Human Leukocyte Antigen-A2 (HLA-A2) restricted genotype.
Participants must be HLA-A2:01 positive in at least one allele tested with a
high-resolution HLA genotyping assay performed in a College of American Pathologists
(CAP)/Clinical Laboratory Improvement Act (CLIA)-certified or equivalent laboratory.
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status
of 0 to 2.
- Laboratory values and cardiac function must meet the protocol specifications.
Exclusion Criteria:
- For AML participants:
- Presence or history of extramedullary disease are ineligible, participants with a
diagnosis of acute promyelocytic leukemia (APL) or BCR-ABL-positive leukemia are
not eligible.
- For NSCLC participants:
- Tumors with epidermal growth factor receptor (EGFR) mutations or anaplastic
lymphoma kinase (ALK) gene rearrangements are not eligible.
- Active/uncontrolled central nervous system (CNS) leukemia/lung cancer are not eligible
for the study.
- History of inflammatory bowel disease, interstitial lung disease (pneumonitis),
myocarditis, Stevens-Johnson syndrome, toxic epidermal necrolysis, solid organ
transplantation, active autoimmune disease (with exceptions of vitiligo, Type I
diabetes mellitus, hypothyroidism, and psoriasis), primary immunodeficiency.
- History of clinical diagnosis of tuberculosis or major immunologic reaction to any
immunoglobulin G (IgG)-containing agent are not eligible.
- Previously received anti-cancer treatment with an agent that targets the immune system
by engaging cluster of differentiation 3 (CD3) are not eligible.
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Recommended Phase 2 Dose (RP2D) of ABBV-184 (Dose-Escalation Phase) |
| Time Frame: | Up to 1 Cycle after the last participant is enrolled in dose escalation phase (Approximately 2 years) |
| Safety Issue: | |
| Description: | The RP2D of ABBV-184 will be determined during the dose-escalation phase of the study. RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data. |
Secondary Outcome Measures
| Measure: | Number of Participants with Adverse Events (AEs) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. |
| Measure: | Change in Laboratory Parameters |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Number of participants with clinically significant change from baseline in clinical laboratory test results like hematology will be reported. |
| Measure: | Change in Vital Signs |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Number of participants with clinically significant change from baseline in vital signs like systolic and diastolic blood pressure will be reported. |
| Measure: | Change in Montreal Cognitive Assessment (MoCA) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | The Montreal Cognitive Assessment (MoCA) is a one page 30-point written test that assesses cognitive function. |
| Measure: | Change in Echocardiogram |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Number of participants with abnormal change from baseline in echocardiogram will be reported. |
| Measure: | Change in Electrocardiogram (ECG) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | 12-lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration. |
| Measure: | Maximum Observed Serum Concentration (Cmax) of ABBV-184 |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Maximum Serum Concentration (Cmax) of ABBV-184. |
| Measure: | Time to Maximum Observed Serum Concentration (Tmax) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Time to Maximum Serum Concentration (Tmax) of ABBV-184. |
| Measure: | Terminal Phase Elimination Rate Constant (β) for ABBV-184 |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Terminal Phase Elimination Rate Constant (β) for ABBV-184. |
| Measure: | Terminal Phase Elimination Half-life (t1/2) of ABBV-184 |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Terminal Phase Elimination Half-life (t1/2) of ABBV-184. |
| Measure: | Area Under the Serum Concentration-Time Curve of ABBV-184 |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Area Under the Serum Concentration-Time Curve of ABBV-184. |
| Measure: | Percentage of Participants With Anti-drug Antibodies (ADAs) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Percentage of Participants With Anti-drug Antibodies (ADAs) |
| Measure: | Duration of Response (DOR) (Dose Expansion Phase) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | DOR is defined as the time between date of first response and the first occurrence of progression or death from any cause, whichever occurs first. |
| Measure: | Progression-free Survival (PFS) (Dose Expansion Phase) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | PFS will be defined as the time between the first dose of any study drug and the first occurrence of progression or death from any cause. |
| Measure: | Relapse-Free Survival (RFS) (Dose Expansion Phase in Participants With AML) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | RFS is defined as the time between date of first response and the first occurrence of progression or death from any cause, whichever occurs first. |
| Measure: | Change in Bone Marrow Blast Count (Dose Expansion Phase in Participants With AML) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Percentage of blast cells in bone marrow. |
| Measure: | Change in Peripheral Blood Blast Count (Dose Expansion Phase in Participants With AML) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | Percentage of blast cells in peripheral blood. |
| Measure: | Objective Response Rate (ORR) (Dose Expansion Phase in Participants With AML) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | ORR is defined as the proportion of participants with complete remission (CR), morphologic complete remission with incomplete blood count recovery (CRi), complete remission with partial hematologic recovery (CRh), complete response with incomplete platelet recovery (CRp), and partial remission (PR). |
| Measure: | Rate of Conversion to Transfusion Independence (Dose Expansion Phase in Participants With AML) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | AML participants will be considered to have converted to transfusion independence if they receive no red blood cell transfusion, platelet transfusion, or growth factors for a 56-day window after beginning study treatment. |
| Measure: | Clinical Benefit Rate (CBR) (Dose Expansion Phase in Participants With NSCLC) |
| Time Frame: | Up to 30 days after last participant complete study drug (Approximately 3 years) |
| Safety Issue: | |
| Description: | CBR is defined as the proportion of participants with a CR, PR, or stable disease (SD) for at least 6 weeks by RECIST 1.1 criteria. |
Details
| Phase: | Phase 1 |
| Primary Purpose: | Interventional |
| Overall Status: | Recruiting |
| Lead Sponsor: | AbbVie |
Trial Keywords
- Advanced Solid Tumors Cancer
- Acute Myeloid Leukemia (AML)
- Non Small Cell Lung Cancer (NSCLC)
- Blood Cancer
- ABBV-184
- Cancer
Last Updated
July 8, 2021
